EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Temporal Association Between COVID ‐19 Vaccination and HBsAg Loss in Chronic Hepatitis B Infection: An Interrupted Time Series Analysis

Jonggi Choi, Allison Carroll, Vy H Nguyen, Megan Michta, Xuan Q Zhang, Young-Suk Lim iD, Raymond T Chung

Alimentary Pharmacology & Therapeutics · 2026

DOI: 10.1111/apt.70733 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2026. Verfasst von Jonggi Choi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Hepatitis B Surface Antigens, COVID-19, COVID-19 Vaccines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Hepatitis B surface antigen (HBsAg) loss, a functional cure in chronic hepatitis (CHB), is rare. Temporal changes in HBsAg loss rates were evaluated in relation to COVID‐19 vaccination rollout in South Korea.

Methods

An interrupted time series (ITS) analysis was performed using electronic health records of 59,946 adults with CHB (2002–2025). Monthly HBsAg loss incidence rates were estimated using a competing risk framework. National COVID‐19 vaccination coverage was used as a surrogate for population‐level exposure. A three‐phase segmental regression model assessed changes before vaccination, during a predefined vaccination effect period (18 months following ≥ 80% of two‐dose coverage), and after this period. Hepatocellular carcinoma (HCC) incidence was analysed as a negative control.

Results

Over 382,509 person‐years, 2483 HBsAg loss events occurred. Pre‐vaccination rates were stable (0.11–0.80 per 100 person‐years). Following the COVID‐19 vaccination rollout, the incidence increased to 0.96 in 2021, peaking at 1.27 in 2022, before declining to 0.93 in 2024. In the ITS model, no baseline trend was observed ( p = 0.606). At the intervention point (November 2021), HBsAg loss rates increased significantly (incidence rate ratio; 1.56; 95% CI 1.26–1.93; p < 0.001). No significant slope change was observed during the vaccination period, while a negative slope change was observed post‐vaccination (coefficient −0.039 per month; p = 0.003). Findings were consistent across sensitivity and subgroup analyses. HCC incidence showed no significant changes.

Conclusion

COVID‐19 vaccination was temporally associated with transiently higher HBsAg loss rates in CHB, followed by attenuation, suggesting a potential population‐level immunomodulatory effect on HBV dynamics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B, ChronicHepatitis B Surface AntigensCOVID-19COVID-19 VaccinesHumansRepublic of KoreaFemaleMaleMiddle AgedInterrupted Time Series AnalysisAdultIncidenceVaccinationAgedCarcinoma, HepatocellularLiver Neoplasms

Stichwörter der Autor:innen

COVID‐19chronic hepatitis Bhepatitis B surface antigen

Substanzen

Hepatitis B Surface AntigensCOVID-19 Vaccines

Autor:innen und Institutionen

  • Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
  • Liver Center, Gastroenterology Division, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Family Medicine, Newton-Wellesley Hospital, Newton, Massachusetts, USA.

ORCID-Profile: Young-Suk Lim

Förderung

  • NIAID NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Choi, J., Carroll, A., Nguyen, V. H., Michta, M., Zhang, X. Q., Lim, Y. S., & Chung, R. T. (2026). Temporal Association Between COVID ‐19 Vaccination and HBsAg Loss in Chronic Hepatitis B Infection: An Interrupted Time Series Analysis. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70733

Vancouver

Choi J, Carroll A, Nguyen VH, Michta M, Zhang XQ, Lim YS, et al. Temporal Association Between COVID ‐19 Vaccination and HBsAg Loss in Chronic Hepatitis B Infection: An Interrupted Time Series Analysis. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.70733

BibTeX
@article{Choi2026,
  author = {Choi, Jonggi and Carroll, Allison and Nguyen, Vy H and Michta, Megan and Zhang, Xuan Q and Lim, Young-Suk and Chung, Raymond T},
  title = {Temporal Association Between COVID ‐19 Vaccination and HBsAg Loss in Chronic Hepatitis B Infection: An Interrupted Time Series Analysis},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2026},
  doi = {10.1111/apt.70733}
}
Kostenlos starten →